Connection

Michael Zile to Aged

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Aged.
Michael Zile
Connection Strength
2.827
Aged
  1. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020 Dec; 43(12):1501-1510.
    View in: PubMed
    Score: 0.059
  2. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 08 04; 76(5):503-514.
    View in: PubMed
    Score: 0.058
  3. Baroreflex Activation Therapy in Patients With Heart?Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020 07 07; 76(1):1-13.
    View in: PubMed
    Score: 0.058
  4. Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. Am J Cardiol. 2019 09 01; 124(5):756-762.
    View in: PubMed
    Score: 0.054
  5. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.
    View in: PubMed
    Score: 0.053
  6. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 05; 11(5):e004446.
    View in: PubMed
    Score: 0.050
  7. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
    View in: PubMed
    Score: 0.050
  8. Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. Physiol Rep. 2017 Nov; 5(20).
    View in: PubMed
    Score: 0.048
  9. Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. J Palliat Med. 2017 10; 20(10):1068-1073.
    View in: PubMed
    Score: 0.047
  10. Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. Circ Heart Fail. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.045
  11. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.042
  12. Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. Circ Heart Fail. 2016 Jan; 9(1):e002543.
    View in: PubMed
    Score: 0.042
  13. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct; 17(10):1066-74.
    View in: PubMed
    Score: 0.041
  14. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015 Apr 07; 131(14):1247-59.
    View in: PubMed
    Score: 0.040
  15. Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. JACC Heart Fail. 2014 Oct; 2(5):512-22.
    View in: PubMed
    Score: 0.039
  16. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2014 Apr; 2(2):123-30.
    View in: PubMed
    Score: 0.037
  17. Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail. 2013 May; 6(3):508-16.
    View in: PubMed
    Score: 0.035
  18. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011 Dec 06; 124(23):2491-501.
    View in: PubMed
    Score: 0.032
  19. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.031
  20. Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. J Card Fail. 2011 Apr; 17(4):282-91.
    View in: PubMed
    Score: 0.030
  21. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011 May; 4(3):246-56.
    View in: PubMed
    Score: 0.030
  22. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30; 121(12):1393-405.
    View in: PubMed
    Score: 0.028
  23. Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). J Heart Lung Transplant. 2010 Jan; 29(1):86-92.
    View in: PubMed
    Score: 0.028
  24. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008 Sep 30; 118(14):1433-41.
    View in: PubMed
    Score: 0.026
  25. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail. 2008 Dec; 14(10):816-23.
    View in: PubMed
    Score: 0.025
  26. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.024
  27. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.022
  28. Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis. 2005 Mar-Apr; 47(5):307-13.
    View in: PubMed
    Score: 0.020
  29. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):707-14.
    View in: PubMed
    Score: 0.016
  30. Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF. PLoS One. 2022; 17(1):e0262479.
    View in: PubMed
    Score: 0.016
  31. Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nat Commun. 2022 01 11; 13(1):203.
    View in: PubMed
    Score: 0.016
  32. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 09 11; 398(10304):991-1001.
    View in: PubMed
    Score: 0.016
  33. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.016
  34. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug; 110(8):1334-1349.
    View in: PubMed
    Score: 0.015
  35. Incidence and Outcomes of Pneumonia in Patients With Heart?Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
    View in: PubMed
    Score: 0.015
  36. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circ Heart Fail. 2021 04; 14(4):e007901.
    View in: PubMed
    Score: 0.015
  37. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. J Am Coll Cardiol. 2001 Mar 15; 37(4):1080-4.
    View in: PubMed
    Score: 0.015
  38. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
    View in: PubMed
    Score: 0.015
  39. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021 05; 23(5):776-784.
    View in: PubMed
    Score: 0.015
  40. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. Am Heart J. 2021 07; 237:45-53.
    View in: PubMed
    Score: 0.015
  41. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail. 2021 04; 8(2):1706-1710.
    View in: PubMed
    Score: 0.015
  42. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.015
  43. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. Am J Med. 2021 06; 134(6):797-804.
    View in: PubMed
    Score: 0.015
  44. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug; 110(8):1234-1248.
    View in: PubMed
    Score: 0.015
  45. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. JAMA. 2020 10 20; 324(15):1522-1531.
    View in: PubMed
    Score: 0.015
  46. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 11; 22(11):2093-2101.
    View in: PubMed
    Score: 0.015
  47. Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. Am J Med. 2021 04; 134(4):e252-e263.
    View in: PubMed
    Score: 0.015
  48. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.
    View in: PubMed
    Score: 0.015
  49. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 12; 22(12):2370-2379.
    View in: PubMed
    Score: 0.015
  50. Loop Diuretic Prescription and 30-Day?Outcomes in Older Patients With?Heart?Failure. J Am Coll Cardiol. 2020 08 11; 76(6):669-679.
    View in: PubMed
    Score: 0.015
  51. Myocardial Infarction in Heart?Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 08; 8(8):618-626.
    View in: PubMed
    Score: 0.014
  52. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.
    View in: PubMed
    Score: 0.014
  53. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart?Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 05; 8(5):372-381.
    View in: PubMed
    Score: 0.014
  54. Covariate adjusted reanalysis of the I-Preserve trial. Clin Res Cardiol. 2020 Nov; 109(11):1358-1365.
    View in: PubMed
    Score: 0.014
  55. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.014
  56. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.014
  57. Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.014
  58. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.014
  59. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020 02 04; 141(5):338-351.
    View in: PubMed
    Score: 0.014
  60. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.014
  61. Randomized trial of partial versus complete chordal preservation methods of mitral valve replacement: A preliminary report. Circulation. 1999 Nov 09; 100(19 Suppl):II90-4.
    View in: PubMed
    Score: 0.014
  62. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
    View in: PubMed
    Score: 0.014
  63. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.014
  64. Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
    View in: PubMed
    Score: 0.014
  65. Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
    View in: PubMed
    Score: 0.013
  66. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 08; 21(8):974-984.
    View in: PubMed
    Score: 0.013
  67. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
    View in: PubMed
    Score: 0.013
  68. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
    View in: PubMed
    Score: 0.013
  69. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The?PARADIGM-HF?Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.013
  70. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 03; 12(3):e005766.
    View in: PubMed
    Score: 0.013
  71. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
    View in: PubMed
    Score: 0.013
  72. Income Inequality and Outcomes in Heart?Failure: A Global Between-Country Analysis. JACC Heart Fail. 2019 04; 7(4):336-346.
    View in: PubMed
    Score: 0.013
  73. Differential Impact of Heart Failure With?Reduced Ejection Fraction on?Men?and?Women. J Am Coll Cardiol. 2019 01 08; 73(1):29-40.
    View in: PubMed
    Score: 0.013
  74. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018 12 11; 138(24):2763-2773.
    View in: PubMed
    Score: 0.013
  75. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
    View in: PubMed
    Score: 0.013
  76. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019 01; 21(1):40-49.
    View in: PubMed
    Score: 0.013
  77. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.013
  78. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018 10; 11(10):e005133.
    View in: PubMed
    Score: 0.013
  79. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 12; 20(12):1701-1709.
    View in: PubMed
    Score: 0.013
  80. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019 01; 21(1):23-36.
    View in: PubMed
    Score: 0.013
  81. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. Am J Med. 2018 12; 131(12):1473-1481.
    View in: PubMed
    Score: 0.013
  82. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. Am Heart J. 2018 11; 205:1-11.
    View in: PubMed
    Score: 0.013
  83. Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept. J Card Fail. 2019 01; 25(1):67-71.
    View in: PubMed
    Score: 0.013
  84. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 07; 11(7):e004962.
    View in: PubMed
    Score: 0.013
  85. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.
    View in: PubMed
    Score: 0.013
  86. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
    View in: PubMed
    Score: 0.012
  87. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018 03; 15(3):e1002541.
    View in: PubMed
    Score: 0.012
  88. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.012
  89. Cardiac macrophages promote diastolic dysfunction. J Exp Med. 2018 02 05; 215(2):423-440.
    View in: PubMed
    Score: 0.012
  90. Type of Atrial Fibrillation and Outcomes in?Patients With Heart Failure and Reduced?Ejection?Fraction. J Am Coll Cardiol. 2017 Nov 14; 70(20):2490-2500.
    View in: PubMed
    Score: 0.012
  91. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.012
  92. Heart Rate and Outcomes in Hospitalized?Patients With Heart Failure With Preserved Ejection?Fraction. J Am Coll Cardiol. 2017 Oct 10; 70(15):1861-1871.
    View in: PubMed
    Score: 0.012
  93. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.012
  94. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017 07 06; 377(1):41-51.
    View in: PubMed
    Score: 0.012
  95. Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. Heart Vessels. 2017 Oct; 32(10):1202-1213.
    View in: PubMed
    Score: 0.012
  96. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 04 14; 38(15):1132-1143.
    View in: PubMed
    Score: 0.012
  97. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
    View in: PubMed
    Score: 0.012
  98. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017 Mar 07; 38(10):742-750.
    View in: PubMed
    Score: 0.011
  99. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
    View in: PubMed
    Score: 0.011
  100. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.
    View in: PubMed
    Score: 0.011
  101. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.011
  102. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017 01; 19(1):129-137.
    View in: PubMed
    Score: 0.011
  103. Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.011
  104. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail. 2016 Oct; 22(10):753-60.
    View in: PubMed
    Score: 0.011
  105. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016 Nov 01; 37(41):3167-3174.
    View in: PubMed
    Score: 0.011
  106. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan; 23(1):20-28.
    View in: PubMed
    Score: 0.011
  107. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
    View in: PubMed
    Score: 0.011
  108. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.011
  109. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail. 2016 08; 18(8):1021-31.
    View in: PubMed
    Score: 0.011
  110. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.
    View in: PubMed
    Score: 0.011
  111. The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. Int J Cardiol. 2016 Jul 15; 215:521-6.
    View in: PubMed
    Score: 0.011
  112. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.011
  113. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.011
  114. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.011
  115. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Feb; 4(2):152-158.
    View in: PubMed
    Score: 0.011
  116. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med. 2015 Dec 03; 373(23):2289-90.
    View in: PubMed
    Score: 0.011
  117. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10; 66(19):2059-2071.
    View in: PubMed
    Score: 0.010
  118. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. J Card Fail. 2016 Apr; 22(4):283-93.
    View in: PubMed
    Score: 0.010
  119. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep; 17(9):925-35.
    View in: PubMed
    Score: 0.010
  120. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 07; 36(38):2576-84.
    View in: PubMed
    Score: 0.010
  121. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul; 8(4):717-24.
    View in: PubMed
    Score: 0.010
  122. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):478-486.
    View in: PubMed
    Score: 0.010
  123. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 07; 36(30):1990-7.
    View in: PubMed
    Score: 0.010
  124. Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circ Heart Fail. 2015 Jul; 8(4):733-40.
    View in: PubMed
    Score: 0.010
  125. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):487-496.
    View in: PubMed
    Score: 0.010
  126. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC Heart Fail. 2015 Jun; 3(6):429-441.
    View in: PubMed
    Score: 0.010
  127. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015 Aug; 17(8):809-17.
    View in: PubMed
    Score: 0.010
  128. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.
    View in: PubMed
    Score: 0.010
  129. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015 May; 17(5):510-7.
    View in: PubMed
    Score: 0.010
  130. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail. 2015 Feb; 17(2):169-76.
    View in: PubMed
    Score: 0.010
  131. A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. J Cardiol. 2015 Sep; 66(3):253-62.
    View in: PubMed
    Score: 0.010
  132. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015 Jan 06; 131(1):43-53.
    View in: PubMed
    Score: 0.010
  133. Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. Radiology. 2015 Apr; 275(1):80-8.
    View in: PubMed
    Score: 0.010
  134. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2014 Nov; 16(11):1175-82.
    View in: PubMed
    Score: 0.010
  135. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014 Nov; 7(6):953-9.
    View in: PubMed
    Score: 0.010
  136. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol. 2014 Sep 16; 64(11):1106-13.
    View in: PubMed
    Score: 0.010
  137. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014 Nov; 7(6):960-6.
    View in: PubMed
    Score: 0.010
  138. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11):993-1004.
    View in: PubMed
    Score: 0.010
  139. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct; 16(10):1096-103.
    View in: PubMed
    Score: 0.010
  140. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.010
  141. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014 Sep; 7(9):870-8.
    View in: PubMed
    Score: 0.010
  142. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014 Dec 21; 35(48):3442-51.
    View in: PubMed
    Score: 0.010
  143. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul; 16(7):817-25.
    View in: PubMed
    Score: 0.009
  144. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014 Jul; 16(7):778-87.
    View in: PubMed
    Score: 0.009
  145. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014 Jun; 16(6):671-7.
    View in: PubMed
    Score: 0.009
  146. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 May; 16(5):535-42.
    View in: PubMed
    Score: 0.009
  147. Systolic and diastolic mechanics in stress cardiomyopathy. Circulation. 2014 Apr 22; 129(16):1659-67.
    View in: PubMed
    Score: 0.009
  148. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Feb 11; 63(5):447-56.
    View in: PubMed
    Score: 0.009
  149. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014 Jan; 35(1):42-7.
    View in: PubMed
    Score: 0.009
  150. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014 Feb; 127(2):132-9.
    View in: PubMed
    Score: 0.009
  151. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013 Oct; 26(10):1234-41.
    View in: PubMed
    Score: 0.009
  152. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med. 2013 Feb; 126(2):150-61.
    View in: PubMed
    Score: 0.009
  153. Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. Circ Heart Fail. 2012 Nov; 5(6):803-11.
    View in: PubMed
    Score: 0.008
  154. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
    View in: PubMed
    Score: 0.008
  155. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20; 380(9851):1387-95.
    View in: PubMed
    Score: 0.008
  156. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
    View in: PubMed
    Score: 0.008
  157. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol. 2012 Oct 15; 110(8):1150-5.
    View in: PubMed
    Score: 0.008
  158. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012 Mar 01; 35(3):233-44.
    View in: PubMed
    Score: 0.008
  159. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012 Mar 01; 5(2):217-25.
    View in: PubMed
    Score: 0.008
  160. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
    View in: PubMed
    Score: 0.008
  161. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011 Sep; 4(5):561-8.
    View in: PubMed
    Score: 0.008
  162. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep; 4(5):569-77.
    View in: PubMed
    Score: 0.008
  163. Left ventricular diastolic function and exercise capacity in community-dwelling adults =65 years of age without heart failure. Am J Cardiol. 2011 Sep 01; 108(5):735-40.
    View in: PubMed
    Score: 0.008
  164. Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. J Card Fail. 2011 May; 17(5):366-73.
    View in: PubMed
    Score: 0.008
  165. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May; 4(3):324-31.
    View in: PubMed
    Score: 0.008
  166. Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol. 2011 Jan 15; 107(2):321-4.
    View in: PubMed
    Score: 0.007
  167. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011 Jan; 4(1):27-35.
    View in: PubMed
    Score: 0.007
  168. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb; 16(2):128-34.
    View in: PubMed
    Score: 0.007
  169. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 04; 359(23):2456-67.
    View in: PubMed
    Score: 0.006
  170. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation. 2008 Sep 16; 118(12):1241-9.
    View in: PubMed
    Score: 0.006
  171. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol. 2008 Jul 15; 102(2):203-6.
    View in: PubMed
    Score: 0.006
  172. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008 Mar 18; 51(11):1073-9.
    View in: PubMed
    Score: 0.006
  173. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008 Feb; 10(2):149-56.
    View in: PubMed
    Score: 0.006
  174. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan; 155(1):113.e1-8.
    View in: PubMed
    Score: 0.006
  175. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
    View in: PubMed
    Score: 0.006
  176. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol. 2007 Feb 15; 99(4):460-4.
    View in: PubMed
    Score: 0.006
  177. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
    View in: PubMed
    Score: 0.006
  178. Myocardial mechanisms causing heart failure early after cardiac transplantation. Transplant Proc. 2006 Nov; 38(9):2999-3003.
    View in: PubMed
    Score: 0.006
  179. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 01; 114(5):397-403.
    View in: PubMed
    Score: 0.005
  180. Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation. 2005 Nov 15; 112(20):3107-14.
    View in: PubMed
    Score: 0.005
  181. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005 May 10; 111(18):2306-12.
    View in: PubMed
    Score: 0.005
  182. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005 Apr; 11(3):191-5.
    View in: PubMed
    Score: 0.005
  183. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol. 1984 Feb; 3(2 Pt 1):235-42.
    View in: PubMed
    Score: 0.005
  184. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003 Oct; 9(5):354-63.
    View in: PubMed
    Score: 0.005
  185. Preliminary report on high thoracic epidural analgesia: relationship between its therapeutic effects and myocardial blood flow as assessed by stress thallium distribution. J Cardiothorac Vasc Anesth. 2000 Dec; 14(6):657-61.
    View in: PubMed
    Score: 0.004
  186. Effect of catheter positioning on the variability of measured gradient in aortic stenosis. Cathet Cardiovasc Diagn. 1993 Dec; 30(4):287-92.
    View in: PubMed
    Score: 0.002
  187. Aortic valve resistance as an adjunct to the Gorlin formula in assessing the severity of aortic stenosis in symptomatic patients. J Am Coll Cardiol. 1992 Dec; 20(7):1517-23.
    View in: PubMed
    Score: 0.002
  188. Dialysis-induced alterations in left ventricular filling: mechanisms and clinical significance. Am J Kidney Dis. 1991 Mar; 17(3):277-85.
    View in: PubMed
    Score: 0.002
  189. Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 1987 May 01; 59(12):1131-7.
    View in: PubMed
    Score: 0.001
  190. Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Nov 01; 58(10):1046-50.
    View in: PubMed
    Score: 0.001
  191. Comparison of left and right ventricular end-systolic pressure-volume relations in congestive heart failure. J Am Coll Cardiol. 1985 Jun; 5(6):1326-34.
    View in: PubMed
    Score: 0.001
  192. Vasodilator effect on right ventricular function in congestive heart failure and pulmonary hypertension: end-systolic pressure--volume relation. Am J Cardiol. 1984 Jul 01; 54(1):132-6.
    View in: PubMed
    Score: 0.001
  193. Immunologic tests of value in diagnosis. 1. Acute phase reactants and autoantibodies. Postgrad Med. 1981 Aug; 70(2):163-78.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.